2001 Nobel Prize in Chemistry(1)
Reason for Award
for research on chirally catalysed hydrogenation reactions
Laureates
United States of America
Japan
Explanation
In chemistry, molecules can be "chiral," meaning they look like our right and left hands and cannot be perfectly overlapped. When medicines are produced, the right-hand and left-hand forms often act differently in the body, so they must be separated. William Knowles and Ryoji Noyori discovered how to use a special helper molecule called a catalyst to make only the desired "right-hand" form in large amounts. Their method carefully controls a reaction called hydrogenation, in which hydrogen gas is added to the target molecule. Thanks to this discovery, important drugs such as L-DOPA for Parkinson’s disease can now be manufactured more safely and efficiently.
Related Keywords
chirality
Chirality refers to a three-dimensional arrangement that cannot be superimposed on its mirror image, just like the difference between right and left hands. Because many biomolecules appear in only one enantiomeric form, biological response, smell, and taste can vary drastically between the two. Asymmetric synthesis therefore aims to preferentially create the desired enantiomer. Asymmetric hydrogenation uses chiral catalysts to insert hydrogen with high stereocontrol, generating chirality in the product. The concept is central to pharmaceuticals, agrochemicals, and advanced materials and forms a cornerstone of sustainable chemistry.
enantiomeric excess
Enantiomeric excess (ee) quantifies the numerical difference between two mirror-image forms; 100 % ee means only one enantiomer is present. High ee maximizes therapeutic benefit while reducing side effects in drug molecules. Catalysts developed by Knowles and Noyori routinely reach 97–100 % ee, surpassing industrial purity requirements. ee is determined by polarimetry, chiral HPLC, and other analytical tools and serves as a key metric when evaluating catalyst performance. Modern research even applies machine learning to predict ee before experimentation.
DiPAMP–rhodium catalyst
DiPAMP is a chiral diphosphine ligand that forms a highly efficient asymmetric hydrogenation catalyst when complexed with Rh(I). Its P-Rh-P bite angle and steric profile selectively stabilize one transition state, giving over 97 % ee in the synthesis of an L-DOPA precursor. DiPAMP-Rh exhibits fast turnover and robustness on an industrial scale, marking the first large-scale commercial route employing asymmetric catalysis. Numerous structural analogues have since been designed for pharmaceuticals and fragrance intermediates. DiPAMP thus stands as a textbook prototype for chiral ligand design.
BINAP
BINAP, short for 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, possesses axial chirality arising from its twisted biaryl framework. Ru(BINAP) complexes serve as versatile catalysts for asymmetric hydrogenation of carbonyls, imines, and more. High stereocontrol stems from BINAP’s rigid torsion angle and electronic tuning, which bias the reaction pathway. Industrially, Takasago’s asymmetric menthol process and other large-scale syntheses employ BINAP catalysts at multi-ton levels annually. Modified BINAP derivatives such as SEGPHOS and DIFLUORPHOS continue to push the frontier of catalyst performance.
L-DOPA
L-DOPA (3,4-dihydroxy-L-phenylalanine) is an essential drug for treating Parkinson’s disease. Traditional production required many steps and racemate separation, but Knowles’ asymmetric hydrogenation dramatically shortened the route and reduced waste. High-purity L-DOPA serves as a precursor to dopamine, alleviating motor symptoms by replenishing dopamine levels in the brain. A reliable synthetic route freed supply from plant extraction, ensuring consistent global availability. L-DOPA remains on the WHO list of essential medicines and continues to improve the quality of life for countless patients.